VolitionRX Limited (VNRX): Price and Financial Metrics

VolitionRX Limited (VNRX): $2.38

0.05 (+2.15%)

POWR Rating

Component Grades














  • Sentiment is the dimension where VNRX ranks best; there it ranks ahead of 59.7% of US stocks.
  • The strongest trend for VNRX is in Value, which has been heading down over the past 148 days.
  • VNRX ranks lowest in Value; there it ranks in the 6th percentile.

VNRX Stock Summary

  • Volitionrx Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.4% of US listed stocks.
  • With a price/sales ratio of 1,988.68, Volitionrx Ltd has a higher such ratio than 99.79% of stocks in our set.
  • Revenue growth over the past 12 months for Volitionrx Ltd comes in at 1,213.4%, a number that bests 99.17% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Volitionrx Ltd are TFFP, LXRX, VXRT, ASND, and OTIC.
  • Visit VNRX's SEC page to see the company's official filings. To visit the company's web site, go to www.volition.com.

VNRX Valuation Summary

  • VNRX's price/sales ratio is 3024.1; this is 26544.05% higher than that of the median Healthcare stock.
  • VNRX's price/sales ratio has moved NA NA over the prior 116 months.
  • VNRX's price/sales ratio has moved NA NA over the prior 116 months.

Below are key valuation metrics over time for VNRX.

Stock Date P/S P/B P/E EV/EBIT
VNRX 2021-08-31 3024.1 6.6 -8.3 -7.2
VNRX 2021-08-30 3013.8 6.5 -8.3 -7.2
VNRX 2021-08-27 3041.4 6.6 -8.4 -7.3
VNRX 2021-08-26 2996.6 6.5 -8.2 -7.2
VNRX 2021-08-25 2922.4 6.3 -8.0 -6.9
VNRX 2021-08-24 2894.8 6.3 -8.0 -6.9

VNRX Growth Metrics

    Its 3 year price growth rate is now at -2.63%.
  • Its 2 year price growth rate is now at 87.05%.
  • Its year over year net income to common stockholders growth rate is now at -16.19%.
VNRX's revenue has moved up $82,915 over the prior 67 months.

The table below shows VNRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 0.082915 -19.17901 -23.91666
2021-06-30 0.058007 -18.80059 -21.10812
2021-03-31 0.038419 -17.83049 -20.61849
2020-12-31 0.013433 -16.46424 -20.35212
2020-09-30 0.006313 -16.3279 -18.77229
2020-06-30 0.022834 -15.54587 -18.6252

VNRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VNRX has a Quality Grade of D, ranking ahead of 5.68% of graded US stocks.
  • VNRX's asset turnover comes in at 0.002 -- ranking 424th of 680 Pharmaceutical Products stocks.
  • CDTX, KALA, and NVS are the stocks whose asset turnover ratios are most correlated with VNRX.

The table below shows VNRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.002 1 -4.279
2021-03-31 0.001 1 -4.727
2020-12-31 0.001 1 -5.183
2020-09-30 0.000 1 -4.958
2020-06-30 0.001 1 -5.040
2020-03-31 0.001 1 -4.625

VNRX Stock Price Chart Interactive Chart >

Price chart for VNRX

VNRX Price/Volume Stats

Current price $2.38 52-week high $4.14
Prev. close $2.33 52-week low $2.08
Day low $2.32 Volume 4,335
Day high $2.38 Avg. volume 90,289
50-day MA $2.72 Dividend yield N/A
200-day MA $3.05 Market Cap 128.02M

VolitionRX Limited (VNRX) Company Bio

VolitionRX Limited, a clinical-stage life sciences company, focuses on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The company is based in Singapore.

VNRX Latest News Stream

Event/Time News Detail
Loading, please wait...

VNRX Latest Social Stream

Loading social stream, please wait...

View Full VNRX Social Stream

Latest VNRX News From Around the Web

Below are the latest news stories about Volitionrx Ltd that investors may wish to consider to help them evaluate VNRX as an investment opportunity.

Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022

Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its quarterly Emerging Growth Invitational investor conference on February 24, 2022. The conference, which is open to all retail and institutional investors, will consist of a series of twenty five

Yahoo | February 15, 2022

MTM Investment Management, LLC Buys PowerShares QQQ Trust Ser 1, FIRST TR SMALL CAP, Amplify ...

Investment company MTM Investment Management, LLC (Current Portfolio) buys PowerShares QQQ Trust Ser 1, FIRST TR SMALL CAP, Amplify CPW Enhanced Dividend Income ETF, Archer-Daniels Midland Co, T.

Yahoo | February 8, 2022

Volition Nu.Q blood test combo detects colorectal cancer

VolitionRx <> said two large scale studies showed that its blood test Nu.Q, when used with Fecal Immunochemical Test ((FIT)), can detect colorectal cancer and all high-risk

Seeking Alpha | January 20, 2022

Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the results of two large scale clinical studies, which show that the company's Nu.Q® assays, when used in conjunction with the Fecal Immunochemical Test (FIT), can detect colorectal cancer and all high-risk advanced adenomas in symptomatic patients, and thereby reduce unnecessary colonoscopies. The studies also demonstrated that the company's Nu.Q® assays can improve the detection of high-r

Yahoo | January 20, 2022

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the December 16th Life Sciences Virtual Investor Conference are now available for on-demand viewing.

Yahoo | December 20, 2021

Read More 'VNRX' Stories Here

VNRX Price Returns

1-mo -5.56%
3-mo -17.07%
6-mo -31.61%
1-year -34.25%
3-year -26.32%
5-year -30.00%
YTD -24.20%
2021 -19.28%
2020 -17.93%
2019 161.88%
2018 -38.44%
2017 -35.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8494 seconds.